Literature DB >> 15246204

Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.

Maria Serena Longhi1, Yun Ma, Dimitrios P Bogdanos, Paul Cheeseman, Giorgina Mieli-Vergani, Diego Vergani.   

Abstract

BACKGROUND/AIMS: CD4(+) lymphocytes constitutively expressing the IL-2-receptor alpha-chain (CD25) regulate the activation of CD4 and CD8 autoreactive T-cells by suppressing their proliferation and effector function. The aim of this study is to: (1) measure the percentage of CD4(+)CD25(+) T-cells (T-regs) in patients with autoimmune liver disease at presentation and during remission, (2) correlate their frequency with disease activity, (3) determine their ability to expand and (4) to inhibit interferon-gamma (IFNgamma) production by CD4(+)CD25- T-cells.
METHODS: 41 patients were studied. Percentage of T-regs was determined on peripheral blood mononuclear cells (PBMCs) by triple-colour flow cytometry; their ability to expand by exposing PBMCs to a T-cell expander (CD3/CD28 Dynabeads); their immunoregulatory function by measuring their ability to suppress IFNgamma production by CD4(+)CD25(-) T-cells.
RESULTS: T-regs were significantly less in patients than in controls, and at diagnosis than during remission. Their percentage was inversely correlated with titres of anti-liver kidney microsomal and soluble liver antigen autoantibodies. T-regs ability to expand was significantly lower in patients than in controls, but that to suppress IFNgamma production by CD4(+)CD25(-) T-cells was maintained.
CONCLUSIONS: Decreased T-regs numbers and ability to expand may favour the emergence of liver-targeted autoimmunity, despite preserved suppressor function. Treatment should aim at increasing T-regs number.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246204     DOI: 10.1016/j.jhep.2004.03.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  123 in total

Review 1.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

2.  New Approaches for Studying Alcoholic Liver Disease.

Authors:  Jun Xu; Xiao Liu; Bin Gao; Michael Karin; Hidekazu Tsukamoto; David Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2014-09-14

3.  Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution.

Authors:  A Perrella; L Vitiello; L Atripaldi; P Conti; C Sbreglia; S Altamura; T Patarino; R Vela; G Morelli; P Bellopede; C Alone; L Racioppi; O Perrella
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 4.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

5.  The role of Ifng in alterations in liver gene expression in a mouse model of fulminant autoimmune hepatitis.

Authors:  Michael W Milks; James G Cripps; Heping Lin; Jing Wang; Richard T Robinson; Jennifer L Sargent; Michael L Whitfield; James D Gorham
Journal:  Liver Int       Date:  2009-04-16       Impact factor: 5.828

Review 6.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

7.  Aberrant TGF-β1 signaling contributes to the development of primary biliary cirrhosis in murine model.

Authors:  Bin Liu; Xuan Zhang; Feng-Chun Zhang; Jin-Bao Zong; Wen Zhang; Yan Zhao
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

Review 8.  Cell mediators of autoimmune hepatitis and their therapeutic implications.

Authors:  Aldo J Montano-Loza; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

9.  Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases.

Authors:  Masanori Koyabu; Kazushige Uchida; Hideaki Miyoshi; Yutaku Sakaguchi; Toshiro Fukui; Hiroki Ikeda; Makoto Takaoka; Junko Hirohara; Akiyoshi Nishio; Yoshiko Uemura; Shinji Uemoto; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2010-01-20       Impact factor: 7.527

Review 10.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.